drugset / Trial / NCT01358266

Study Assessing Double-masked Uveitis Treatment

NCT01358266

Phase 3 Completed 592 enrolled Santen Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.

Timeline

Start
2011-05
Primary completion
2016-09
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sirolimus Small molecule 44 ug Intravitreal
Comparator Sirolimus Small molecule 440 ug Intravitreal
Comparator Sirolimus Small molecule 880 ug Intravitreal

Indications